Tradestie Institutional Equity Comparison Engine

FEMY vs RNAZ โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RNAZ Overall Edge

RNAZ Captures Institutional Edge (1โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to TransCode Therapeutics, Inc. Common Stock (RNAZ) driven by superior Growth & Margin while FEMY counters with relative strength in Momentum & Technical. Fundamentally, FEMY trades at N/M Forward P/E with -763.9% operating margin (-18.9% YoY revenue) versus RNAZ at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, FEMY sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against RNAZ sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
FEMY N/M vs RNAZ N/M Fwd P/E
Growth & Margin Winner RNAZ
Op Margin -763.9% vs 0.0% ยท YoY -18.9% vs +0.0%
Momentum & Technical Winner FEMY
1Y +54.8% vs -85.6% ยท 52W Pos 17% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
1M Return -22.42%
1Y Return +54.78%
Forward P/E N/M
Unified AI Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
RNAZ NASDAQ
TransCode Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.35
+2.27% 1D
Market Cap $22.3M
1M Return -20.59%
1Y Return -85.64%
Forward P/E N/M
Unified AI Score
50.3 / 100 HOLD
Tech 53.0 Fund 48.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FEMY +54.78% RNAZ -85.64% Spread: +138.75 pp (FEMY Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
FEMY TTM Op. Margin: -763.9% RNAZ TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FEMY vs RNAZ. Trailing 12-month operating profitability (FEMY -763.9% vs RNAZ 0.0%) and valuation multiples (FEMY N/M vs RNAZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FEMY (2) vs RNAZ (5)
Institutional Metric FEMY RNAZ Criterion Row Winner
Market Capitalization Scale $11.9M $22.3M Larger Scale RNAZ
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -18.9% +0.0% Higher Growth RNAZ
Operating Margin (TTM) Profitability -763.9% 0.0% Higher Margin RNAZ
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -425.0% -59.3% Higher ROE RNAZ
52-Week Range Position Momentum 17% ($0โ€“$6) 0% ($1โ€“$13) Stronger Trend FEMY
Beta / 30D Volatility Risk Regime 4.01ฮฒ ยท 72% Vol 0.96ฮฒ ยท 63% Vol Lower Realized Risk RNAZ
Unified Institutional Score Composite Signal 52.6 / 100 (HOLD) 50.3 / 100 (HOLD) Higher Composite FEMY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FEMY vs RNAZ Buy Guide
FEMY UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live FEMY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RNAZ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RNAZ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FEMY nor RNAZ registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.